Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.

However, the difference in microtumor volume in experiment 2 was highly significant, 0.010 ± 0.003 mm 3 versus 3.79 ± 1.24 mm 3 (treated versus controls, respectively), i.e., a 99.7% reduction ( p < 0.001).

also in 132,142 other papers